Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTomco Energy Regulatory News (TOM)

Share Price Information for Tomco Energy (TOM)

Share Price is delayed by 15 minutes
Get Live Data
0.0265    -0.0025 (-8.62%)
Bid:
0.026
Ask:
0.027
Spread: 0.001 (3.846%)
Market Cap: £1.60m
TOM Live PriceLast checked at - London Stock Exchange

Intraday Tomco Energy Share Chart

Quadrise Testing Update

23 Sep 2021 07:30

RNS Number : 6878M
TomCo Energy PLC
23 September 2021
 

23 September 2021

TOMCO ENERGY PLC

("TomCo" or the "Company")

 

Quadrise Testing Update

TomCo Energy plc (AIM: TOM), the US operating oil development group focused on using innovative technology to unlock unconventional hydrocarbon resources, is pleased to note the announcement made earlier today by Quadrise Fuels International plc ("Quadrise") providing an update on its testing of a produced oil sample supplied by TomCo's 100% owned subsidiary Greenfield Energy LLC ("Greenfield") taken from the Petroteq Oil Sands Plant ("POSP") during Greenfield's operation of the POSP.

Quadrise has reported that an extensive programme of testing on the Greenfield oil sample was completed at the Quadrise Research Facility ("QRF") in Essex on schedule, and a report has now been issued to Greenfield.

Quadrise noted that the ability to produce commercial MSAR® and bioMSAR™ fuels from the produced oil has been confirmed from its testing. Simulations of storage and handling of both fuels were also completed during the programme. The testing at the QRF confirmed the suitability of the heavy sweet oil for the commercial production of MSAR® and bioMSAR™ fuels in Utah for potential power and marine end-user applications domestically and internationally.

Quadrise further noted that this testing concludes the proof-of-concept work that was scheduled in Phase 1 of the Commercial Trial Agreement between Greenfield and Quadrise announced on 18 August 2020. TomCo will now review the report and it is expected that Greenfield and Quadrise will enter into discussions regarding potential future trials and deployment of the technology to produce MSAR® and/or bioMSAR™ fuel at a commercial scale.

Commenting, John Potter, CEO of TomCo, said: "We are delighted that Quadrise has now completed its testing programme. We are encouraged by the positive confirmations issued by Quadrise today and we look forward to continuing to work with Quadrise as we progress our plans for Greenfield."

 

Enquiries:

 

TomCo Energy plc

Malcolm Groat (Chairman) / John Potter (CEO) +44 (0)20 3823 3635

Strand Hanson Limited (Nominated Adviser)

James Harris / Matthew Chandler +44 (0)20 7409 3494

Novum Securities Limited (Broker)

Jon Belliss / Colin Rowbury +44 (0)20 7399 9402

IFC Advisory Limited (Financial PR)

Tim Metcalfe / Florence Chandler +44 (0)20 3934 6630

For further information, please visit www.tomcoenergy.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAFNAALEFEAA
Date   Source Headline
2nd Jul 20217:00 amRNSGreenfield Update
23rd Jun 20217:00 amRNSGrant of Share Options
22nd Jun 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20214:35 pmRNSPrice Monitoring Extension
22nd Jun 20217:00 amRNSInterim Results
14th Jun 20217:00 amRNSGreenfield Update
9th Jun 20217:00 amRNSGreenfield: Conditional Site Purchase Arrangement
7th Jun 20212:05 pmRNSSecond Price Monitoring Extn
7th Jun 20212:00 pmRNSPrice Monitoring Extension
4th Jun 20214:40 pmRNSSecond Price Monitoring Extn
4th Jun 20214:35 pmRNSPrice Monitoring Extension
4th Jun 20212:18 pmRNSDirectorate Change
3rd Jun 20212:06 pmRNSSecond Price Monitoring Extn
3rd Jun 20212:00 pmRNSPrice Monitoring Extension
1st Jun 202111:05 amRNSSecond Price Monitoring Extn
1st Jun 202111:00 amRNSPrice Monitoring Extension
1st Jun 20219:05 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
1st Jun 20217:00 amRNSGreenfield Update
26th May 20217:00 amRNSGreenfield Update
18th May 20217:00 amRNSGreenfield Update
4th May 20214:40 pmRNSSecond Price Monitoring Extn
4th May 20214:35 pmRNSPrice Monitoring Extension
27th Apr 20217:00 amRNSGreenfield Update
19th Apr 20217:00 amRNSAppointment of Non-Executive Director
13th Apr 202112:43 pmRNSHolding(s) in Company
12th Apr 20213:25 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSUpdate re Greenfield and Director Disclosure
18th Feb 20217:00 amRNSFinal Results for the year ended 30 September 2020
21st Jan 20217:00 amRNSPOSP Update
6th Jan 20217:00 amRNSPOSP Restart
18th Dec 20207:00 amRNSGreenfield Update
2nd Dec 20207:00 amRNSGreenfield Update
30th Nov 20204:04 pmRNSHolding(s) in Company
30th Nov 202012:42 pmRNSHolding(s) in Company
30th Nov 202012:14 pmRNSHolding(s) in Company
30th Nov 20209:42 amRNSHolding(s) in Company
27th Nov 20203:11 pmRNSHolding(s) in Company
26th Nov 202010:37 amRNSHolding(s) in Company
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSPlacing to raise £3.5 million
2nd Nov 20202:06 pmRNSSecond Price Monitoring Extn
2nd Nov 20202:00 pmRNSPrice Monitoring Extension
2nd Nov 20207:00 amRNSBoard Changes
1st Oct 20203:15 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSGreenfield Update
16th Sep 20207:00 amRNSGreenfield Pre-FEED Report
26th Aug 20201:34 pmRNSGreenfield Update
19th Aug 20202:20 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.